A Remarkable Opportunity

In 1996, Dr. Wayne Lautt identified a hormone secreted by the liver during digestion. The hormone is called “hepatic insulin-sensitizing substance” or HISS. When HISS is missing, a person will progress from prediabetes to diabetes over time. Dr. Lautt (Professor Emeritus, Department of Pharmacology and Therapeutics at the University of Manitoba) concluded that if we could replace the HISS hormone or stimulate its secretion, we could conquer diabetes while tackling obesity.

This breakthrough is now poised to change the paradigm of diabetes management, which is currently based on insulin. Dr. Lautt’s work is based on many years of preclinical studies, verification in humans with international collaborators, and a small clinical trial. The science has been published nationally and internationally in 40 peer-reviewed papers. The results have validated Dr. Lautt’s hypothesis and have led to new hope for the prevention of type 2 diabetes.

Dr. Lautt’s work has attracted CAD$17.3 million in grants and corporate support. Operating as a private company called SciMar Ltd. since 2009, Dr. Lautt and his colleagues are moving forward with more advanced clinical testing to meet the stringent requirements of Canadian and American regulators. Since 2018, the company has attracted CAD$7 million from 39 different investors. 

Since the company’s birth in 2009, Dr. Lautt and his team have taken measured steps in the lab to validate the science and develop a product pipeline that addresses growing global health needs.

The company now employs a team of 15 scientists, executives, business development specialists, and contractors. In October 2018, SciMar established a commercial research laboratory at one of Canada’s leading medical facilities, the Albrechtsen Research Centre at St. Boniface Hospital in Winnipeg. Additionally, SciMar re-branded its product pipeline around Nutrient Partitioning (NuPa), the science of understanding how our bodies metabolize nutrients.

Since 2016, SciMar Ltd. has made remarkable progress scientifically, organizationally, and commercially. The company’s current valuation is CAD$95 million.


  • SciMar’s intellectual property and product pipeline are patented in 10 countries, including the United States, countries of the European Union, and China where type 2 diabetes rates are growing dramatically. The intellectual property, and therefore your investment, is well protected.
  • Major pharmaceutical companies have expressed interest in SciMar’s work and the data from the next round of clinical trials. Their interest is enhanced by the fact that most of their patents for current diabetes drugs will expire in the next few years.
  • Currently, about $550 billion is spent annually on diabetes drugs.
  • SciMar will report progress to investors regularly. The CEO is available for one-on-one meetings and phone calls with interested parties.

About the Wellness Transformation Network

The Wellness Transformation Network (WTN) is SciMar’s outreach initiative designed to improve community well-being, gather data to inform our scientific research, and introduce NuPa Test to our organizational partners and to thousands of Manitobans. This video explains why the WTN is so important to SciMar investors.

For further information, contact:

Mick Lautt, Chief Executive Officer SciMar Ltd. (204) 701-2000 mick.lautt@scimar.ca

Type 2 diabetes has an enormous impact on patients and their families, not to mention health care policy and funding. The disease presents an enormous social burden and I am happy to see that a new paradigm in managing it might be on the horizon. I trust the SciMar team and am impressed by the science. Most important, I’m excited about the impact we could have.

Dr. Scott Kish

Manitoba Family Physician of the Year Award, 2018 SciMar Investor

This information has been prepared for the purposes of providing general information about the opportunity to invest in SciMar. Please note that investment in SciMar is limited by and subject to compliance with all applicable securities laws, including the exemptions set out in National Instrument 45-106 – Prospectus Exemptions. This is not an invitation to subscribe for shares or invest in the Company and is not solicitation of any such investment. The information provided above and elsewhere on this website is being provided on the understanding that in order to make an investment you must qualify for an exemption under such applicable securities laws.